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Dear Dr. Anthanont Pimjai,
We have carefully read with great interest your letter to the
Editor with comments and concerns about the results of our
study [1]. We would like to make some remarks.
All women included in our study, both in the study and in
the control group, were Caucasian [2]. Therefore, the study
group was homogeneous in terms of ethnicity, so no ethnic
variations could be observed.
However, we agree with you that the available data on the
potential influence of adiponectin on cardiovascular disease is
rather equivocal. Aung et al. in their meta-analysis (14,063
CVD patients enrolled) showed a strong positive association
of adiponectin with cardiovascular mortality (n=11 studies,
overall pooled effect estimate=1.69 [1.35–2.10]) [3]. That
was in accordance with a study by Schondorf et al. as well
as our research [2, 4].
Furthermore, it is worth noticing that some studies have
suggested that high-molecular-weight adiponectin is a stron-
ger risk factor for cardiovascular diseases than total
adiponectin level [5]. In another study, serum adiponectin
levels were found to be inversely correlated with intima-
media thickness as a marker of carotid atherosclerosis [6].
As Dr Pimjai mentioned before, other adequately powered
studies failed to identify adiponectin as a cardiovascular risk
factor.
Some researchers claim that these contradictory results in
this field might be caused by confounding factors, sex and age
of the analyzed subjects, different oligomers of adiponectin
tested, other methodological issues (various assays: radioimmu-
noassays or ELISAs), or handling of laboratory samples.[7]
We agree with Dr Pimjai that further, well-designed studies
are needed to clarify the full relationship between adiponectin
and the risk of cardiovascular disease.
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